3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Pancreatic Neoplasms
9
Colonic Neoplasms
5
Ovarian Neoplasms
3
Melanoma
3
Colorectal Neoplasms
3
Carcinoma, Hepatocellular
3
Carcinoma
3
Breast Neoplasms
3
Stomach Neoplasms
2
Liver Neoplasms
2
Fibrolamellar hepatocellular carcinoma
2
Esophageal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Adenocarcinoma
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasms, Squamous Cell
1
Neoplasms, Plasma Cell
1
Neoplasm Metastasis
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Chondrosarcoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Merkel Cell
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
25
Nivolumab
20
atezolizumab
8
Magnetic Resonance Spectroscopy
7
Ipilimumab
7
Specimen Handling
5
Paclitaxel
5
Fluorodeoxyglucose F18
4
Cyclophosphamide
4
Carboplatin
4
fludarabine
3
durvalumab
3
avelumab
3
Interleukin-2
3
Gemcitabine
3
Docetaxel
3
130-nm albumin-bound paclitaxel
3
tislelizumab
2
spartalizumab
2
regorafenib
2
epacadostat
2
cabozantinib
2
aldesleukin
2
Taxes
2
Pemetrexed
2
FAPI-46
2
Cisplatin
2
Albumin-Bound Paclitaxel
2
zanidatamab
1
veliparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
poly ICLC
×
Gastrointestinal
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled